Screening programs for the identification of early stage BRCA can significantly improve patient outcome because of the treatment benefit of early detection. In addition, accurate markers for treatment responses (disease recurrence) can refocus treatment approaches in a timely fashion based upon sensitive detection of treatment efficacy.

Screening programs for the identification of early stage CRC and pre-neoplastic conditions can significantly improve disease outcome.

Screening for early stage LUAD can improve disease outcomes, help define treatment pathways and provide a tool to monitor surgical and therapeutic interventions.

This is extremely difficult to diagnose and is often detected at a late stage with metastatic spread. Early, accurate diagnosis is critical and tools are required for early detection.

Identification of patients with a poor prognosis or predicting who will respond to therapies including ADT and 177Lu-PSMA-therapy will facilitate stratification of those likely to benefit from specific treatment regimens. Molecular markers that are predictive and prognostic will benefit management potentially extending survival and reducing unwanted therapeutic side-effects.

Early pancreatic cancer is often asymptomatic. Diagnosis rarely occurs until disease is advanced thus survival is limited. PCR-based blood tests for pancreatic cancer identification and assessment of treatment response provide much-needed tools. These will enable detection of early disease prior to symptom development and facilitate disease monitoring.

There are currently no effective circulating diagnostic or prognostic biomarkers. Molecular biomarkers that can be used to monitor the efficacy of surgery or identify whether immunotherapies are effective are key tools. Early detection of recurrent disease or the ability to accurately determine response (or lack thereof) to a therapy can significantly improve disease outcome.

Accurate determination of minimal residual disease and identification of individuals who may relapse is a critical unmet need. Early detection of changes in clonality or molecular markers of poor prognosis can significantly improve management and extend survival.

The NETest is an established, validated blood test that functions both as a “rule-out” diagnostic test (to confirm absence of a tumor or residual disease) and as prognostic test to measure therapeutic responses to individual treatments. The NETest is also effective in the identification of neuroendocrine differentiation in lung and prostate cancers.